Prostate cancer Posts - Page 10 of 80 on Medivizor
Navigation Menu

Prostate cancer Posts on Medivizor

Evaluating the effectiveness of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread

Evaluating the effectiveness of enzalutamide plus androgen deprivation therapy in metastatic hormone-sensitive prostate cancer by pattern of metastatic spread

Posted by on Jan 17, 2021 in Prostate cancer | 0 comments

In a nutshell This study examined the impact of the pattern of metastatic spread on the effectiveness of enzalutamide in combination with androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that the combination has good outcomes in men with bone and/or lymph node...

Read More

Evaluating combination therapies for metastatic hormone-sensitive prostate cancer.

Evaluating combination therapies for metastatic hormone-sensitive prostate cancer.

Posted by on Jan 17, 2021 in Prostate cancer | 0 comments

In a nutshell This study was carried out to look at the use of combining radiotherapy (RT), systemic therapy (ST; whole-body treatment), and androgen deprivation therapy (ADT) for prostate cancer (PC) that is hormone-sensitive and has spread. The authors concluded that ADT plus RT led to better outcomes in patients with low-volume disease. Some...

Read More

Evaluating the effects of abiraterone acetate in combination with androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer.

Evaluating the effects of abiraterone acetate in combination with androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer.

Posted by on Jan 10, 2021 in Prostate cancer | 0 comments

In a nutshell This study examined the effects of abiraterone acetate (AA; Zytiga) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that AA and ADT combination improves the outcomes in these patients. Some background Patients with mHSPC have...

Read More

Evaluating long-term outcomes for proton therapy in men with localized prostate cancer.

Evaluating long-term outcomes for proton therapy in men with localized prostate cancer.

Posted by on Dec 31, 2020 in Prostate cancer | 0 comments

In a nutshell This study examined the long-term effectiveness and safety of proton therapy for localized prostate cancer. The data showed that proton therapy has favorable outcomes in these patients. Some background Localized prostate cancer (PCa) is a form of cancer that has not spread beyond the prostate gland. PCa can be treated by...

Read More

Evaluating long-term active surveillance for early-stage prostate cancer.

Evaluating long-term active surveillance for early-stage prostate cancer.

Posted by on Dec 28, 2020 in Prostate cancer | 0 comments

In a nutshell This study was carried out to assess the long-term outcomes of men diagnosed with prostate cancer (PC) undergoing active surveillance (AS) and factors that predicted the risk of their cancer spreading (metastasizing). The authors found that AS is a safe and viable option for men with low-risk and carefully-selected intermediate-risk...

Read More

Reviewing the effects of bisphosphonates or RANKL-inhibitors for men with prostate cancer and bone metastases

Reviewing the effects of bisphosphonates or RANKL-inhibitors for men with prostate cancer and bone metastases

Posted by on Dec 26, 2020 in Prostate cancer | 0 comments

In a nutshell The study summarized the outcomes of bisphosphonates and RANKL-inhibitors as supportive treatment in men with prostate cancer (PC) and bone metastases (BM). The authors recommended that a balance between the efficacy and safety of such therapies must be considered for preventing skeletal events in such patients. Some background Men whose...

Read More

Should patients with prostate cancer get androgen deprivation therapy before or after radiotherapy?

Should patients with prostate cancer get androgen deprivation therapy before or after radiotherapy?

Posted by on Dec 20, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of giving androgen deprivation therapy (ADT) before or after radiotherapy (RT) for prostate cancer (PCa). The study found that treatment with RT followed by ADT increased patient survival without the spread of the disease. Some background PCa can often spread to other locations within the...

Read More

Seeking men with metastatic castration-resistant prostate cancer to trial a combination therapy

Seeking men with metastatic castration-resistant prostate cancer to trial a combination therapy

Posted by on Dec 15, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is evaluating the effectiveness and safety of combining nivolumab (Opdivo) with docetaxel (Taxotere) and prednisone (Deltasone) in men with metastatic castration-resistant prostate cancer (mCRPC). The main outcomes to be evaluated will be survival without cancer worsening and overall survival. The details CRPC is a difficult...

Read More

Does androgen-receptor inhibitor therapy increase the risk of falling and broken bones in patients with prostate cancer?

Does androgen-receptor inhibitor therapy increase the risk of falling and broken bones in patients with prostate cancer?

Posted by on Dec 13, 2020 in Prostate cancer | 0 comments

In a nutshell This study investigated if treating patients who have prostate cancer with androgen receptor inhibitors (ARIs) increased their risk of falling and breaking their bones. The study found that patients who received ARI were more likely to have a fall or fracture compared to other treatments. Some background Prostate cancer (PCa)...

Read More

Searching for patients with advanced prostate cancer to trial an experimental combination treatment.

Searching for patients with advanced prostate cancer to trial an experimental combination treatment.

Posted by on Dec 13, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is looking to examine the safety and effectiveness of a new drug called CYH33 in combination with olaparib (Lynparza) for the treatment of advanced solid tumors including prostate cancer. The main outcomes that are to be measured are side effects and the response rate to the treatment. This trial is being carried out in Houston,...

Read More

Evaluating long-term outcomes of MRI-guided ultrasound ablation for prostate cancer.

Evaluating long-term outcomes of MRI-guided ultrasound ablation for prostate cancer.

Posted by on Dec 13, 2020 in Prostate cancer | 0 comments

In a nutshell This study was carried out to assess the long-term safety and effectiveness of magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) in patients with localized prostate cancer. The authors found that TULSA was safe and effective, with preserved quality of life. Some background Prostate cancer is one...

Read More

Comparing whole-pelvis vs prostate only radiotherapy in patients with high-risk prostate cancer

Comparing whole-pelvis vs prostate only radiotherapy in patients with high-risk prostate cancer

Posted by on Dec 6, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared the use of radiotherapy for prostate cancer in two areas: the prostate only, or the whole pelvis. The results showed that, for high-risk patients, radiotherapy of the whole pelvis improved patient outcomes. Some background For patients with medium or high-risk prostate cancer, the standard treatment is...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor